Science

From hormone to medical context.

Explore GH biology, compare hormone replacement with GLP-1 medicines and secretagogues, and examine the evidence for recovery, aging, and fitness.

Compare compounds →Recovery, aging & fitness

What are GH and IGF-1?

Growth hormone (GH) is made by the pituitary gland. It supports childhood growth and has metabolic roles throughout life. GH stimulates production of insulin-like growth factor 1 (IGF-1) in the liver and other tissues; IGF-1 helps mediate effects on tissues including bone and cartilage.

Somatropin is a manufactured form of human growth hormone used as a medicine. A description of the hormone’s biology does not establish the quality or suitability of any particular brand.

Testing needs context

GH secretion varies over time. Clinicians interpret medical history, appropriate laboratory testing, and other findings together. A low IGF-1 result can have causes other than growth hormone deficiency.

Where treatment has evidence

For adults with confirmed GH deficiency, treatment may improve body composition, skeletal health, exercise capacity, and quality of life. Benefits vary. Stimulation testing is usually needed to confirm adult deficiency, with exceptions determined by the clinical circumstances.

Individualized assessment is essential: evidence from patients with a diagnosed deficiency cannot simply be applied to healthy people.

Aging and performance claims

The Endocrine Society’s scientific statement finds that growth hormone treatments are not established anti-aging interventions. In studies of healthy older adults, modest body-composition changes came with adverse effects. A change in measured lean mass does not by itself prove a meaningful improvement in strength or function.

Three questions worth asking

What diagnosis explains my symptoms, and what evidence supports it?
Which outcomes matter for my situation, and how would they be measured?
How will benefits, adverse effects, and alternative treatments be reviewed?

Continue to safety →

Sources & further reading

Endocrine Society · Growth hormone deficiency ↗Endocrine Society · Adult growth hormone deficiency guideline ↗Endocrine Society · Hormones and Aging scientific statement ↗

These resources explain general medicine and safety information. They do not verify CELTROPE’s authorization, composition, or batch quality.

Compare treatments

HGH, GLP-1 medicines & GH secretagogues.

The right comparison starts with the condition being treated. These compounds do not solve the same problem, and a hormone-level change is not the same as a proven patient benefit.

Where direct HGH replacement has a distinct role

Somatropin supplies the hormone itself. For a patient with confirmed deficiency, this avoids relying on a secretagogue to make an impaired pituitary release sufficient GH. Clinical guidelines support individualized replacement in suitable patients. This mechanism and evidence base distinguish it from experimental secretagogue use; they do not make HGH the best treatment for every goal.

Adult GH-deficiency guideline ↗

Regulatory examples refer to US labeling and research status checked in November 2026. Local authorizations may differ. General evidence about somatropin does not establish CELTROPE’s approval, quality, or clinical equivalence.

Different mechanisms, different evidence, different clinical purposes
Compound	Class	How it works	Evidence / clinical role	What patients should understand
Somatropin (HGH)Source ↗	Direct hormone replacement	Supplies GH rather than asking the pituitary to release it.	Established treatment for confirmed GH deficiency in appropriate patients; indications depend on the exact product.	It has a specific replacement role. That does not establish superiority for obesity, healthy aging, or sport.
SemaglutideCurrent label ↗	GLP-1 receptor agonist	Acts through GLP-1 signaling, including appetite and glucose regulation.	Authorized formulations have weight-management and other product-specific indications.	For obesity, an indicated obesity medicine addresses a different clinical goal. It does not replace missing GH.
TirzepatideCurrent label ↗	GIP / GLP-1 receptor agonist	Acts through two incretin receptors.	Zepbound has indications for eligible adults with obesity/overweight and for certain patients with obesity and obstructive sleep apnea.	It is a metabolic treatment, not a GH secretagogue or hormone replacement.
RetatrutideDevelopment status ↗	Investigational triple receptor agonist	Targets GIP, GLP-1, and glucagon receptors.	Under clinical investigation; the manufacturer reports it is not approved.	Research findings do not establish the safety or quality of products sold outside trials.
CJC-1295Human study ↗ FDA safety review ↗	GHRH analogue	Stimulates endogenous GH release through the GHRH pathway.	Short human studies measured GH and IGF-1 increases, not long-term wellness outcomes.	DAC and non-DAC names should not be treated as interchangeable evidence. FDA identifies limited clinical data and safety concerns.
IpamorelinEarly research ↗ FDA safety review ↗	GH secretagogue / GHRP-receptor agonist	Stimulates endogenous GH release through a different pathway from GHRH.	Early selectivity findings include animal research; these do not prove long-term benefit or safety in patients.	Claims that it is a risk-free, gentler equivalent to somatropin are not established. FDA identifies important safety-data gaps.
TesamorelinPrescribing information ↗	GHRH analogue	Stimulates the pituitary GH pathway.	Egrifta is indicated for excess abdominal fat in adults with HIV-associated lipodystrophy.	Its label explicitly excludes general weight-loss management. Long-term cardiovascular safety is not established.
HexarelinHuman study ↗	GH-releasing peptide	Stimulates GH release; acute human experiments also found effects on ACTH, cortisol, and prolactin.	Small physiological studies demonstrate hormone responses.	A larger GH response is not proof of better recovery, muscle growth, longevity, or long-term safety.
SermorelinFDA historical determination ↗	GHRH analogue	Stimulates pituitary GH release.	Geref historically had pediatric GH-deficiency and diagnostic indications; those products were discontinued.	FDA found the withdrawal was not for safety or effectiveness reasons. That history does not validate present-day adult wellness claims or every compounded preparation.

On smaller screens, swipe the table horizontally. Keyboard users can focus the table area to scroll.

Confirmed GH deficiency

Direct replacement may improve body composition, skeletal health, exercise capacity, and quality of life. The decision depends on diagnosis and individual risk—not a desire to maximize IGF-1.

Guideline ↗

Obesity treatment

Semaglutide and tirzepatide have authorized weight-management formulations. GH replacement is not interchangeable with those therapies, and comparing results from unrelated patient populations cannot establish a universal winner.

Semaglutide label ↗ Tirzepatide label ↗

Secretagogue comparisons

GHRH analogues and GHRPs stimulate release through different pathways. A “more natural pulse” or a larger hormone rise does not, by itself, prove better health outcomes or fewer adverse effects.

CJC study ↗ Ipamorelin research ↗

Wellness, aging & performance

What is measured—and what remains uncertain.

Widespread use and personal testimonials can explain public interest. They cannot replace controlled evidence about benefits and harms.

Aging and longevity

Age-related reductions in GH are not automatically a disease requiring replacement. Studies in healthy older adults have found modest body-composition changes alongside adverse effects; these findings do not demonstrate longer life or rejuvenation. The Endocrine Society does not endorse GH as an anti-aging intervention.

Scientific statement ↗

Recovery and connective tissue

A small, short study in healthy men found increased tendon collagen synthesis, without increased myofibrillar protein synthesis. This is a biological signal—not proof that routine HGH treatment heals injuries faster, prevents reinjury, or shortens return-to-sport time.

Collagen study ↗

Fitness and bodybuilding

Trials in healthy adults show changes in lean and fat mass, but generally not improvements in strength or aerobic capacity. One trial found a modest sprint-capacity improvement; other performance measures did not significantly improve, and the effect was not maintained after treatment stopped. This does not establish a safe bodybuilding strategy.

Meta-analysis ↗ Randomized trial ↗

Lean mass is not all muscle

Lean mass includes body water. In the recreational-athlete trial, increased extracellular water contributed to the apparent lean-mass gain. A scan or scale change should not be described as new contractile muscle without supporting evidence.

Body-composition findings ↗

Energy, sleep, skin, and “feeling better”

Quality-of-life benefits in diagnosed deficiency do not establish the same benefits in otherwise healthy people. Persistent fatigue, poor sleep, or impaired recovery deserve evaluation for their underlying causes, rather than assuming low GH.

Clinical context ↗ Aging evidence ↗

A patient’s overview

Questions that matter before treatment.

Assessment and expectations

What diagnosis is being treated, and how was it established?
Is this exact medicine authorized for that condition locally?
Which outcomes will be measured: symptoms, function, laboratory results, or body composition?
What would make the clinician reconsider or stop treatment?

Risk and follow-up

Somatropin can cause swelling, joint symptoms, and other adverse effects. A clinician needs to review medical history and contraindications, including cancer, certain serious illnesses, and diabetic eye disease. This is not a complete risk list.

Ask about follow-up tests, relevant symptoms, and whom to contact. Severe allergic symptoms require emergency care.

Patient medicine information ↗

Product identity and handling

Obtain the current patient leaflet and confirm the formulation, batch details, expiration, and storage requirements with a pharmacist. Mixing instructions and in-use storage periods cannot safely be copied from another brand. A realistic carton or a QR code does not prove medicine quality.

Read the packaging guide →

Combining medicines

Different mechanisms are not a reason to combine products on your own. A comparison chart is not a treatment plan. Have a clinician assess the full medication list and the intended indication for each medicine; do not assume one drug cancels another’s risks.

Read the safety guide →

How to read this overview

Links beside each comparison lead to labeling, primary studies, or professional guidance. Studies differ in population, duration, and outcomes. This overview does not claim that the listed compounds have been compared head-to-head for all goals, and it does not recommend doses, cycles, or combinations.